Levosimendan Tillomed

Active Ingredient:: Levosimendan
Origin:: EU

Levosimendan Tillomed (Levosimendan)

Q: What is Levosimendan Tillomed used for?

Levosimendan Tillomed is an intravenous medication used primarily to treat acute decompensated heart failure. It improves cardiac contractility and reduces vascular resistance, helping patients with severe heart failure symptoms regain hemodynamic stability.

Q: How does levosimendan work?

Levosimendan sensitizes cardiac troponin C to calcium, which strengthens heart muscle contraction without increasing intracellular calcium. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, causing vasodilation and lowering both preload and afterload.

Q: What is the usual dose of Levosimendan Tillomed?

The dosing regimen for Levosimendan Tillomed is determined by the prescribing clinician based on the patient’s condition, weight, and response. The prescriber sets the infusion rate and duration according to approved guidelines and individual needs.

Q: Is Levosimendan safe during pregnancy or breastfeeding?

Safety data for levosimendan in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and under close medical supervision.

Q: How do I order Levosimendan Tillomed from GNH India?

To request Levosimendan Tillomed, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Q: How does levosimendan compare with other inotropes?

Unlike traditional catecholamine inotropes, levosimendan enhances contractility by calcium sensitization and provides vasodilation through potassium‑channel activation. This dual action can improve cardiac output with a lower risk of increasing myocardial oxygen consumption, offering a distinct therapeutic profile compared with drugs such as dobutamine or milrinone.

Q: What are the storage and handling requirements for Levosimendan Tillomed?

Levosimendan Tillomed should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use to maintain stability.

Q: How is Levosimendan Tillomed administered?

Levosimendan Tillomed is given by intravenous infusion. The initial loading dose is typically administered over 10 minutes, followed by a continuous maintenance infusion. Administration is performed by qualified healthcare professionals in a monitored clinical setting.

Q: What are the most serious risks associated with levosimendan?

The most serious risks include severe hypotension, ventricular arrhythmias, myocardial ischemia, and rare allergic reactions. Patients should be closely monitored for blood pressure, heart rhythm, and signs of ischemia throughout the infusion.

Q: Who should not receive levosimendan?

Levosimendan is contraindicated in patients with systolic blood pressure below 90 mmHg, severe obstructive cardiomyopathy, or known hypersensitivity to the drug. Caution is also advised for individuals with significant renal or hepatic impairment, and it should be avoided in those with uncontrolled arrhythmias.

Levosimendan, the active ingredient in Levosimendan Tillomed, is a calcium sensitizer / inodilator presented as an injection for intravenous use. It treats acute decompensated heart failure in adult patients.
GNH India supplies Levosimendan Tillomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Manufacturer / TM Owner

Tillomed Pharma Gmbh

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Levosimendan acts on the cardiovascular system to improve cardiac performance in acute heart failure settings.
Acute decompensated heart failure: enhances cardiac output and relieves symptoms of congestion.
Cardiogenic shock (off‑label): supports myocardial contractility when conventional therapy is insufficient.
Post‑cardiac surgery low cardiac output syndrome: improves hemodynamics and facilitates weaning from mechanical support.

How It Works

Levosimendan binds to cardiac troponin C, increasing its sensitivity to calcium and thereby strengthening myocardial contraction without raising intracellular calcium levels. Simultaneously, it opens ATP‑sensitive potassium channels in vascular smooth muscle, causing vasodilation and reducing cardiac preload and afterload.

Side Effects

Levosimendan may be associated with several adverse reactions.

Common Side Effects

Hypotension: reduction in blood pressure, especially after rapid infusion.
Headache: mild to moderate intensity.
Nausea: occasional gastrointestinal upset.
Tachycardia: increased heart rate during therapy.

Serious or Rare Side Effects

Ventricular arrhythmias: potentially life‑threatening rhythm disturbances.
Myocardial ischemia: chest pain due to reduced coronary perfusion.
Severe hypotension: profound blood pressure drop requiring intervention.
Allergic reactions: rash, pruritus, or anaphylaxis in susceptible individuals.

Precautions & Warnings

Levosimendan requires careful monitoring and specific safety measures.

Blood pressure monitoring: observe for hypotension during and after infusion.
Cardiac rhythm surveillance: watch for arrhythmias, especially in patients with pre‑existing conduction disorders.
Renal impairment adjustment: consider dose modification in severe renal dysfunction.
Hepatic dysfunction caution: use with caution in patients with significant liver disease.
Contraindication in severe hypotension: avoid in patients with systolic BP <90 mmHg.
Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Levosimendan can interact with other cardiovascular agents, requiring attention to dosing and monitoring.

Major Interactions (Avoid)

Concomitant vasodilators (e.g., nitroglycerin): may cause additive hypotension.
Strong CYP3A4 inhibitors (e.g., ketoconazole): increase levosimendan plasma levels.
Other calcium sensitizers: risk of excessive inotropic effect.

Moderate Interactions (Monitor Closely)

Diuretics: may potentiate volume depletion and hypotension.
Beta‑blockers: may blunt desired chronotropic response.
ACE inhibitors or ARBs: require blood pressure monitoring for additive effects.

Frequently Asked Questions

Levosimendan Tillomed is an intravenous medication used primarily to treat acute decompensated heart failure. It improves cardiac contractility and reduces vascular resistance, helping patients with severe heart failure symptoms regain hemodynamic stability.

Levosimendan sensitizes cardiac troponin C to calcium, which strengthens heart muscle contraction without increasing intracellular calcium. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, causing vasodilation and lowering both preload and afterload.

The dosing regimen for Levosimendan Tillomed is determined by the prescribing clinician based on the patient’s condition, weight, and response. The prescriber sets the infusion rate and duration according to approved guidelines and individual needs.

Safety data for levosimendan in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and under close medical supervision.

To request Levosimendan Tillomed, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Unlike traditional catecholamine inotropes, levosimendan enhances contractility by calcium sensitization and provides vasodilation through potassium‑channel activation. This dual action can improve cardiac output with a lower risk of increasing myocardial oxygen consumption, offering a distinct therapeutic profile compared with drugs such as dobutamine or milrinone.

Levosimendan Tillomed should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use to maintain stability.

Levosimendan Tillomed is given by intravenous infusion. The initial loading dose is typically administered over 10 minutes, followed by a continuous maintenance infusion. Administration is performed by qualified healthcare professionals in a monitored clinical setting.

The most serious risks include severe hypotension, ventricular arrhythmias, myocardial ischemia, and rare allergic reactions. Patients should be closely monitored for blood pressure, heart rhythm, and signs of ischemia throughout the infusion.

Levosimendan is contraindicated in patients with systolic blood pressure below 90 mmHg, severe obstructive cardiomyopathy, or known hypersensitivity to the drug. Caution is also advised for individuals with significant renal or hepatic impairment, and it should be avoided in those with uncontrolled arrhythmias.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 28 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.